Details of the Drug

General Information of Drug (ID: DMHPYSM)

Drug Name

Ellipticine

Synonyms

ellipticine; 519-23-3; Elliptisine; 5,11-Dimethyl-6H-pyrido[4,3-b]carbazole; NSC 71795; TCMDC-125546; NSC-71795; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazole; ICIG 770; 5,11-Dimethylpyrido[4,3-b]carbazole; CCRIS 2003; CP 5; UNII-117VLW7484; NSC71795; EINECS 208-264-0; CHEMBL123; BRN 0221300; MLS000736786; MLS000028487; CHEBI:4776; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-; CCG-36483; 117VLW7484; SMR000058370; 6H-Pyrido[4,3-b]carbazole,5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazole, 5,11-dimethyl-; SR-01000003083; elliptecine; Ellipticin

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

246.31

Logarithm of the Partition Coefficient (xlogp)

4.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C17H14N2
IUPAC Name: 5,11-dimethyl-6H-pyrido[4,3-b]carbazole
Canonical SMILES: CC1=C2C=CN=CC2=C(C3=C1NC4=CC=CC=C43)C
InChI: InChI=1S/C17H14N2/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17/h3-9,19H,1-2H3
InChIKey: CTSPAMFJBXKSOY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3213
ChEBI ID: CHEBI:4776
CAS Number: 519-23-3
TTD ID: D00DNY

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN ; TOP2B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[2]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[2]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[2]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[2]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[3]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[3]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Gene/Protein Processing	[4]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Regulation of Drug Effects	[5]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Regulation of Drug Effects	[5]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Regulation of Drug Effects	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22.
2	The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs. 2005 Aug;16(7):789-95. doi: 10.1097/01.cad.0000171768.36317.93.
3	The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells. Toxicology. 2018 Apr 1;398-399:1-12.
4	Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases. Toxicology. 2011 Nov 18;289(2-3):91-102. doi: 10.1016/j.tox.2011.07.014. Epub 2011 Aug 6.
5	Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology. 2012 Dec 16;302(2-3):233-41. doi: 10.1016/j.tox.2012.08.004. Epub 2012 Aug 16.